ArticleJournal of inflammation (London, England)2015
The prognostic influence of tumor infiltrating Foxp3(+)CD4(+), CD4(+) and CD8(+) T cells in resected non-small cell lung cancer.
Article in Journal of inflammation (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Prognostic implications of tumor-infiltrating lymphocytes in non-small cell lung cancer: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis.Journal for immunotherapy of cancer · 2018Trial
- AC decoction augments chemotherapy in NSCLC by reshaping the tumor immune microenvironment: attenuating Tregs and enhancing CD8Scientific reports · 2026Article
- Pathologic assessment of resected stage III non-small cell lung cancer after neoadjuvant chemotherapy: identification of additional prognostic factors.Histopathology · 2026Article
- Bacterial membrane-modified cerium oxide nanoboosters enhance systemic antitumor effects of radiotherapy in metastatic triple-negative breast cancer.Journal of nanobiotechnology · 2025Article
- PD-L1International journal of molecular sciences · 2024Article
- Bojungikki-Tang Augments Pembrolizumab Efficacy in Human PBMC-Injected H460 Tumor-Bearing Mice.Life (Basel, Switzerland) · 2024Article
- In situ analysis of CCR8BMC cancer · 2024Article
- PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer.Medicina (Kaunas, Lithuania) · 2024Article
- The relationship between high ratios of CD4/FOXP3 and CD8/CD163 and the improved survivability of metastatic triple-negative breast cancer patients: a multicenter cohort study.BMC research notes · 2024Article
- Is It Unnecessary to Assess Tumor Stroma-Infiltrating Lymphocytes in Localized Lung Adenocarcinomas?Tanaffos · 2024Article
- [Consensus on Postoperative Recurrence Prediction of Non-small Cell Lung Cancer Based on Molecular Markers].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
- Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes.Cancers · 2022Article
- Functional status and spatial interaction of T cell subsets driven by specific tumor microenvironment correlate with recurrence of non-small cell lung cancer.Frontiers in immunology · 2022Article
- Screening and identifying a novel M-MDSCs-related gene signature for predicting prognostic risk and immunotherapeutic responses in patients with lung adenocarcinoma.Frontiers in genetics · 2022Article
- On the Prognostic Power of Tumor-Infiltrating Lymphocytes - A Critical Commentary.Frontiers in immunology · 2022Article
- Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibition.Cell death discovery · 2021Article
- Difference in the distribution of tumor-infiltrating CD8+ T cells and FOXP3+ T cells between micronodular thymoma with lymphoid stroma and micronodular thymic carcinoma with lymphoid stroma.Pathology international · 2021Article
- T lymphocytes related biomarkers for predicting immunotherapy efficacy in non-small cell lung cancer.Oncology letters · 2021Review
- Effects of Systemic Lidocaine on Postoperative Recovery Quality and Immune Function in Patients Undergoing Laparoscopic Radical Gastrectomy.Drug design, development and therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferent subsets of tumor infiltrating T lymphocytes are believed to play essential role in the immune response to cancer cells. The data of these cells in NSCLC are relatively rare and controversial therefore we aimed to evaluate the infiltration patterns of Foxp3 + CD4+, CD4+ and CD8+ T cells in NSCLC and to analyze their relations to survival.
methodsLung tissue specimens from 80 newly diagnosed and untreated patients who underwent surgery for NSCLC (stages I-III), and 16 control group subjects, who underwent surgery due to recurrent spontaneous pneumothorax, were analyzed. Foxp3 + CD4+, CD4+ and CD8+ T cells in tumor stroma and islets were evaluated immunohistochemically. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS), version 20.0.
resultsTumor infiltrating CD4+, CD8+ T cells were associated with neither overall survival nor disease-free survival. The presence of high tumor stroma infiltrating Foxp3 + CD4+ T cells was independently associated with improved NSCLC patients overall survival (P < 0.05).
conclusionsOur study demonstrated that tumor infiltrating Foxp3 + CD4+ T cells are associated with improved NSCLC patients' survival. In addition our findings highlight a tendency of high CD4+/CD8+ and CD8+/Foxp3 + CD4+ T cells ratio in prolonged NSCLC patients' survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.